ASCO GU 2022

ADC in bladder cancer: defining the future!

Neoadjuvant therapy in UTUC: Good options for selected patients

Role of PARPi in urothelial cancer

PARPi in urothelial cancer: DFS advantage for the DDR+, OS data pending.

Exciting data supports trimodality therapy

Not practice changing, but hypothesis generating.

ADCs will be step-changing in urothelial cancers

Mature data confirm efficacy of maintenance avelumab as standard of care

ADC shape the therapy landscape in urothelial cancer

Follow-up data confirm OS benefit across subgroups

IO escalation results in improved response in met. TCC.

HER2 ERBB2 – entering precision oncology

Patient selection for bladder preservation

Patient selection for adjuvant Nivolumab (TPS vs. CPS)

Ongoing immunotherapy innovation for mCRPC

Do we need testing? Which biomarkers are of relevance?

Triplet vs. doublet: Which patients should we consider?

Theranostics – Presence and future: Vision, PSMAfore, PSMAAddition, TheraP

The future of genetic testing. Somatic vs. germline? International perspectives

Enza beyond progression? Practice changing or not?

Is biomarker development taking a back seat in prostate cancer?

The need for biomarker panels in biopsy decision making

Subgroup analyses confirm the importance of oral daily GnRH Antagonist - relugolix

PSMA and FDG PET as biomarkers for response to LuPSMA

DARO in triplet therapy for CRPC

Should we use arbiraterone and olaparib as 1st line treatment of mCRPC?

PROpel & Magnitude: who wins the race?

Where do PROpel and Magnitude agree?

PSA response correlates with OS and benefits in QoL

Is the dual hormone-backbone the future?

How to improve PSMA based radioligand therapy

Is docetaxel still needed for hormone sensitive mCRPC?

HRR testing: MAGNITUDE vs. PROpel

Should we use arbiraterone and niraparib as 1st line treatment of mCRPC with BRCA1/2 mutation?

Exciting new compound for mCRPC

New therapies and molecular targets in prostate cancer

The importance of conducting HCRA

Triplet-therapy as a novel treatment option

Addition of darolutamide improves OS in met. hormone-sensitive PC

PRESIDE indicates benefit of continuation ENZA + ADT

Treatment options following adjuvant PD1 Therapy: Uncertainty of choices!

Neoadjuvant IO+TKI Treatment: We need more data on efficient IO/TKI combinations

Adjuvant PD1 Therapy confirms significant benefit for high-risk patients. An individual risk benefit assessment is required!

Thoughts on first line treatment options following ASCO GU 2022

Consistent OS benefit confirmed. Consider overtreatment vs. undertreatment!

Adjuvant Pembroluzimab update in kidney cancer

Update in neoadjuvant therapy for kidney cancer

Frontline treatment of metastatic kidney cancer

Microbioma modification and checkpoint inhibition

CheckMate final OS Follow Up and health related QoL

Data gap in 2nd line RCC: what’s new?

Nivo montoherapy followed by Nivi-Ipi resuce

Neoadjuvant avelumab/axitinib - NeoAvAx

Update in adjuvant therapy for kidney cancer